

# 2023 Bioshares Biotech Summit - PROGRAM

## Sunday 23<sup>rd</sup> July

4.00pm	Drinks / Exhibition / Play ( <i>Hobart Real Tennis Club</i> )
5.00pm - 6.00pm	Registration Open ( <i>Hotel Grand Chancellor</i> )
6.30pm onwards	CEO Dinner (Biotech CEOs only) - <i>Rockwall Bar &amp; Grill</i>

## Monday 24<sup>th</sup> July (Hotel Grand Chancellor, Grand Ballroom)

8.00am - 8.45am	<b>Registration Open</b>
9.00am - 9.15am	Introduction, Housekeeping
9.15am - 9.45am	Keynote Address – <b>Yuman Fong</b>

### Session 1: Biotech Leaders Part 1

In this session we will hear from some of the leading, emerging biotech companies on the ASX that have brought their products to market and/or are on the cusp of new product launches. Several of these companies highlight the appeal of the sector generating strong top line growth and some are now on the cusp of profitability. (*Chair: James Berman, Bell Potter*)

9.45am - 10.10am	Teri Thomas, CEO of <b>Volpara Health Technologies</b>
10.10am - 10.30am	James Agnew, CFO of <b>Aroa Biosurgery</b>
10.30am - 11.00am	Chris Behrenbruch, CEO of <b>Telix Pharmaceuticals</b>
11.00am	( <i>Investor breakout with Telix Pharmaceuticals</i> )
11.00am	<b>Break</b>

Sponsored by

**BELL POTTER**

### Session 2: Biotech Leaders Part 2

11.45am - 12.10pm	Kingsley Hall & Anthony Skeats, CEO & COO of <b>Micro-X</b>
12.10pm - 12.30pm	Andrew Shute, Senior VP of Business Development, <b>EBR Systems</b>
12.30pm - 12.55pm	Jon Pilcher, CEO of <b>Neuren Pharmaceuticals</b>
12.55pm - 1.00pm	[ <b>Acuity Capital</b> - Sponsor]

1.00pm **Lunch**

### Session 3: Drug Developers – Finding the Next Neuren Part 1

Neuren Pharmaceuticals has been a stunning success for its investors and the for the Australasian biotech sector. Which company will be the next standout drug development success? With a very active drug development sector, this session will feature the next wave of private and listed drug developers that are moving through the clinical trials development process. (*Chair - Tim Clark, Piper Alderman*)

2.00pm - 2.20pm	Nina Webster, CEO of <b>Dimerix</b>
2.20 pm - 2.40pm	Matt Callahan, Executive Director of <b>Botanix Pharmaceuticals</b>

Sponsored by

 **PiperAlderman**

### Company Feature

2.40pm - 3.00pm	Jeremy Steele, CEO of <b>Control Bionics</b>
-----------------	--

3.00pm - 3.45pm **Break**

3.45pm - 4.15pm **The Mike Hirshorn Address**

## Session 4: The Microbiome & Gut Health

The hidden impact of the gut on multiple diseases and disorders continues to be an underexplored area for drug developers. However, with major deals being conducted in this field, including the US\$10.8 billion acquisition of Prometheus by Merck, and the first microbiome-derived drugs gaining approval, gut health therapeutic and diagnostic companies have a raft of commercial opportunities ahead of them. (Chair - Rebecca Wilson, Ateria Health)

4.15pm - 4.35pm Steven Lydeamore, CEO of **Immuron**  
4.35pm - 4.55pm Luke Reid, CEO of **Microba Life Sciences**  
4.55pm - 5.10pm Malcolm Hebblewhite, CEO of **Atmo Biosciences**  
5.10pm - 5.30pm **Microbiome Panel Discussion**  
*Panellists: Steven Lydeamore, Luke Reid, Malcolm Hebblewhite, Alan Liddle*

Sponsored by



5.30pm - 5.35pm **The Blake Award for Excellence ("The Blakey")**

5.35pm **End of Day 1**

Sponsored by

7.00pm - 11.00pm **Cocktail Reception** (Glen Albyn Estate, by bus from Grand Chancellor Hotel, 15 mins from Hobart CBD)

**FB RICE**



## Tuesday 25<sup>th</sup> July

**Master Classes** (Harbour View Room)

9.15am - 9.55am **Master Class 1** - "Half an hour till market open...Managing the madness of continuous disclosure"

Continuous disclosure is a challenge for all ASX-Listed companies. "Immediate" disclosure of market-sensitive information requires Boards to make quick decisions, in the midst of changing circumstances. For life sciences companies, the added complexities include: providing balanced and clear explanations of highly technical information; juggling disclosure obligations with embargo requirements for thought leadership journals and conferences; and keeping a reasonable flow of announcements over the long development timeline.

*Lis Boyce & Mark Williamson (Piper Alderman), Rebecca Wilson (WE Communications, Alcidion, Ateria Health)*

10.00am - 10.40am **Master Class 2** – ATM Financing with Acuity Capital

At-the-money (ATM) financing has been used in the US since the 1990s and is now available in Australia. It is a low cost, supplementary way for listed biotechs to raise capital, in addition to conventional placements, SPPs and rights issues. Acuity Capital provides this facility in Australia and in this masterclass will explain the mechanism together with recent trends and activity over the last 12 months.

## DAY 2 Sessions (Hotel Grand Chancellor, Grand Ballroom)

### Session 5: The Advancement of Immunotherapies and Cell Therapy

Australian pharma and biotech has been very active in cancer immunotherapies and vaccines. From CSL with the development of Gardasil and the acquisition of Viralytics, the depth of commercial activity in this area continues to advance to the next wave on oncolytic viruses, CAR T cell therapies and novel vaccine technologies. In this session investors will hear from some dynamic companies that are making rapid advances in this field. (Chair: David Nayagam, E&P Financial Group)

11.00am - 11.25am Monil Shah, CBO of **Imugene**  
11.25am - 11.45am Steven Yatomi-Clarke, CEO of **Prescient Therapeutics**  
11.45am - 12.05pm Michael Baker, CEO of **Arovella Therapeutics**  
12.05pm - 12.30pm David Hoey, President & CEO of **Vaxxas**

#### Company Feature

12.30pm - 12.50pm Damien Hawes, Head of Commercial Operations for **HitIQ**

12.50pm - 1.00pm [Sasha Conoplia, BD Manager of Listings, **ASX** - Sponsor]

1.00pm **Lunch**

## Session 6: Drug Developers – Finding the Next Neuren Part 2

Chair: *Lis Boyce (Piper Alderman)*

- 2.00pm - 2.20pm Gary Phillips, CEO of **Pharmaxis**  
2.20pm - 2.40pm Hugh Alsop, CEO of **Kinoxis Therapeutics**  
2.40pm - 3.00pm Liz Dallimore, CEO of **Argenica**  
3.00pm - 3.20pm Steven Gourlay, CEO of **Actinogen Medical**

3.20pm **Break**

## Session 7 – Changing Healthcare Practices Through Better Diagnostics

Several companies are seeking to change global healthcare practises through the introduction of novel diagnostics to prevent and better manage chronic disease. The companies presenting in this session will discuss the commercialisation plans for their products/inventions. What are the commercial challenges to clinical adoption and what are the strategic pathways these companies have in place are some of the aspects that will be discussed. Chair - *Peter Bradley (Qatalyst Consulting)*

- 4.00pm - 4.20pm Otto Buttula, Executive Chairman of **Rhythm Biosciences**  
4.20pm - 4.40pm Richard Lipscombe, CEO of **Proteomics International**  
4.40pm - 4.55pm Sander Bangma, CEO of **Navier Medical**  
4.55pm - 5.15pm Marjan Mikel, CEO of **Respiri**  
5.15pm - 5.30pm Sam Lanyon, Exec Chair of **Lumos Diagnostics**

## Session 8 – Investment Panel

What are the global trends in biotech? When will the next wave of euphoric investor sentiment set its sights on the biotech industry? And what are some of the best picks from Australia's leading biotech analysts and fund managers active in this sector are some of the topics that will be discussed in one of the favourite sessions of the Summit.

Sponsored by



- 5.30pm - 6.00pm **Investment Panel**  
*Mark Pachacz (chair), Scott Power (Morgans), Elyse Shapiro (Canaccord Genuity), Ben Constable (Lumira Ventures), Matt McNamara (Horizon 3 Healthcare), Dr Anubhav Saxena (Bell Potter)*

6.00pm **Closing Comments**

Sponsored by

7.00pm - late **Conference Dinner** (*Henry Jones Art Hotel*)



Media partner



IT Partner

